325
Participants
Start Date
September 30, 2004
Primary Completion Date
February 28, 2007
Study Completion Date
February 28, 2007
Aripiprazole
2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
Local Institution, Birmingham
Local Institution, Little Rock
Local Institution, Costa Mesa
Local Institution, Fresno
Local Institution, Orange
Local Institution, Riverside
Local Institution, Rosemead
Local Institution, Sacramento
Local Institution, Temecula
Local Institution, Washington D.C.
Local Institution, Altamonte Springs
Local Institution, Fort Lauderdale
Local Institution, Hialeah
Local Institution, Jacksonville
Local Institution, Miami
Local Institution, Orange City
Local Institution, Tampa
Local Institution, Atlanta
Local Institution, Honolulu
Local Institution, Chicago
Local Institution, Kansas City
Local Institution, Lexington
Local Institution, Louisville
Local Institution, Lake Charles
Local Institution, Metairie
Local Institution, New Orleans
Local Institution, Somerville
Local Institution, Clinton
Local Institution, Kansas City
Local Institution, Saint Charles
Local Institution, Elmsford
Local Institution, New York
Local Institution, Olean
Local Institution, Rochester
Local Institution, Chapel Hill
Local Institution, Cleveland
Local Institution, Lyndhurst
Local Institution, Oklahoma City
Local Institution, Bala-Cynwyd
Local Institution, Philadelphia
Local Institution, Memphis
Local Institution, Bellaire
Local Institution, DeSoto
Local Institution, Houston
Local Institution, San Antonio
Local Institution, Salt Lake City
Local Institution, Kirkland
Local Institution, Seattle
Local Institution, Spokane
Local Institution, Wauwatosa
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY